A phase I-II trial of multimodality management of bulky gynecologic malignancy. Combined chemoradiosensitization and radiotherapy

Cancer. 1990 Jul 1;66(1):30-4. doi: 10.1002/1097-0142(19900701)66:1<30::aid-cncr2820660107>3.0.co;2-c.

Abstract

Between December 1983 and December 1987, there were 44 patients with bulky, nonresectable squamous cell carcinomas of the gynecologic tract (cervix, 36; vagina, eight) who were treated with concomitant chemotherapy and radiotherapy. Chemotherapy consisted of 5-fluorouracil (5-FU) 1g/m2 given by continuous intravenous infusion on days 1 through 4 and mitomycin C 10 mg/m2 given intravenously on day 1. External-beam irradiation was started on day 1 with a total calculated dose of 5000 cGy in 25 fractions employed. This was followed by brachytherapy. With a mean follow-up of 30.3 months and a median of 28 months, local control has been achieved in 32 of 44 patients (73%). The overall response rate was 88% (3-month partial response, 43%; 3-month complete response, 45%; 8-month partial response, 15%; 8-month complete response, 73%). Analysis of complications by Radiation Therapy Oncology Group (RTOG) criteria did not demonstrate an increase in acute or late complications.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy
  • Drug Evaluation
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / adverse effects
  • Follow-Up Studies
  • Genital Neoplasms, Female / drug therapy
  • Genital Neoplasms, Female / radiotherapy
  • Genital Neoplasms, Female / therapy*
  • Humans
  • Middle Aged
  • Mitomycin
  • Mitomycins / administration & dosage
  • Mitomycins / adverse effects
  • Radiation-Sensitizing Agents / therapeutic use

Substances

  • Antineoplastic Agents
  • Mitomycins
  • Radiation-Sensitizing Agents
  • Mitomycin
  • Fluorouracil